All News
Are Rheums Attending ACR 2020?
ACR 2020 (aka ACR Convergence) is just around the corner, with the opening ceremonies and lecture starting Thursday, November 5th; followed by the full meeting beginning the next morning, Friday November 6th.
Read Article
High Burnout Rates Among Rheumatologists
Bergman and colleagues have studied a large cohort of US rheumatologists and found that nearly half meet at least one criterion defining "burnout" among physicians.
Read Article
Remdesivir FDA Approved for Hospitalized COVID-19
The FDA has approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.
Read Article
Outpatient Visits Return to Pre-COVID Rates
The COVID-19 pandemic dramatically impacted outpatient care - numbers, scope, quality, etc, but a recent study suggests that while COVID has changed the scope of care, the numbers of outpatient visits have risen to near pre-pandemic numbers.
Read Article
TNF Inhibitors or non-TNF Biologics - First Best Choice?
Prospective observational findings from the CORRONA registry of rheumatoid arthritis (RA) patients compared clinical outcomes between initial aggressive therapy using either a tumour necrosis factor inhibitor (TNFi) or a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and tar
Read Article
COVID Transmission from Young to Old
The CDC has analyzed temporal trends in percent positivity by age group in COVID-19 hotspot counties before and after their identification as hotspots.
Read Article
RheumNow Podcast – Bad Disease & Bad Outcomes (10.9.20)
Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com.
Read Article
RheumNow Podcast – Cardiovascular Risk in Psoriatic Disease (9.25.20)
Dr. Jack Cush reviews the news and Journal articles from the past week on RheumNow.com.
Read Article
RheumNow Podcast – The Bad News That’s Fit to Print (8.21.20)
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow: filgotinib rejection, delays in diagnosis, metformin benefits COVID, Abx and IBD, and UPA beats MTX.
Read Article
Are Women in Rheumatology Closing the Gap?
"Fierce, Formidable and Phenomenal" was the tag line used to introduce Vice-Presidential candidate, Kamala Harris. Her introduction followed a review of the increasing role of women in voting, society and politics in America. Has the same been realized by women in academic medicine and rheumatology?
Read Article
Filgotinib Decision Delayed by FDA
On August 18th, Gilead and Galapagos received a complete response letter from the FDA, which will delay consideration of filgotinib for the treatment of moderate-to-severe RA.
Read Article
ACP/AAFP Guidelines on Managing Musculoskeletal Pain
Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended as first-line therapy in a new guideline for treating acute, non-low back pain from musculoskeletal injuries in outpatient settings.
Read Article
RheumNow Podcast - The SARS-CoV-2 Update (8-14-20)
Dr. Jack Cush updates the news and journal articles from the past week on RheumNow.com, with information on enthesitis, nr-Ax-SpA, UAB, Blockbuster Rheum Drugs and use of ACE inhibitors.
Read Article
RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)
Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.
Read Article
Methotrexate Improves Pegloticase Efficacy and Tolerability
The efficacy of intravenous pegloticase (PEG) therapy in gout can be limited by its toxicity, but when coadministered with weekly methotrexate, higher response rates and less toxicity was observed.
Read Article
The Burden of Gout
Danve and Neogi have an editorial in the current Arthritis & Rheumatology about the burden of gout that affects 41 million adults worldwide, according to the Global Burden of Disease Study 2017 (GBD 2017) also published in the same issue.
This makes gout twice as prevalent as rheumatoid arthritis (19 million). This prevalence of this most common inflammatory arthritis is undermined by numerous challenges in the diagnosis and examples of insufficient disease management. The editorial points out the magnitude of the disease and the many challenges facing rheumatologists.
ACR Advice on Reopening Strategies
The American College of Rheumatology (ACR) has issued a guidance document for rheumatologists and rheumatology health professionals to consider as practices, business and patient care begins to reopen in this next phase of the COVID-19 pandemic.
Read Article
ACR Position Statement on Telemedicine
The American College of Rheumatology (ACR) has released an official position statement supporting the role of telemedicine as a tool with the potential to increase access and improve care for patients with rheumatic diseases.
Read Article
Is IL-23 Better than IL-17 Inhibition in Psoriasis?
Data presented at the recent American Academy of Dermatology meeting suggests that interleukin (IL)-23 inhibition with risankizumab was more effective than the IL-17 inhibition (secukinumab) based on a 52 week randomized head-to-head trial in moderate to severe psoriasis patients.
Read Article
TNR Grand Rounds - Update on Biosimilars
This week's Tuesday Nite Rheumatology featured Dr Jonathan Kay (U Mass) who gave an update on Biosimilars and took questions the subject. The program was moderated by Dr. Jack Cush.
Read Article